Study

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer

2026 · primary-comparison · peer reviewed: yes · record 42581230 · PubMed

2 findings kept from this study. Each is one sentence comparing an animal with a human, extracted from the full text, checked against the located page, and adjudicated against the review's definition of an animal-versus-human comparison.

The paper found concordant mechanisms of daraxonrasib resistance in human and murine preclinical models of PDAC.

Concordant · level A · mouse · oncology

“To corroborate these clinical findings, we found, or mechanistically established, concordant mechanisms of daraxonrasib resistance in human and murine preclinical models of PDAC, including mutant KRAS and MYC amplification and RTK upregulation, with these alterations guiding various combination therapy concepts.”
page 1

The majority of key acquired resistance mechanisms identified in human patient ctDNA samples were recapitulated in daraxonrasib-resistant preclinical models.

Concordant · level A · no species named · oncology

“The majority of key acquired resistance mechanisms identified in the EOT ctDNA samples (for example, mutant KRASamp, RTK alterations and MYCamp) were recapitulated in daraxonrasib-resistant preclinical models derived following prolonged RAS(ON) inhibition.”
page 5